Q-omics provides the consensus-scored ABHD14B profile across patient tissues and cancer cell-line models. ABHD14B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ABHD14B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ABHD14B protein abundance shows 30,638 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where ABHD14B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD14B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD14B survival associations across molecular data types. ABHD14B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD14B RNA expression–survival associations across cancer types. High ABHD14B expression shows unfavorable associations in LGG, but favorable associations in UVM, KIRP, CESC, READ and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ABHD14B RNA expression.
This table summarizes ABHD14B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABHD14B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD14B shows lower tumor expression in KIRC, HNSC, LUSC, KICH, UCEC and BRCA. The KIRC box plot shows higher ABHD14B RNA expression in normal versus tumor tissue (log2 FC = −0.685, t-test p < 0.001).
This table shows molecular features associated with ABHD14B in patient tissues and cancer cell lines. In patient samples, ABHD14B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD14B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
